Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 9/20 | 0.50 |
| ▸ | DRD4 | P21917 | 7/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | PIM1 | P11309 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 7/20 | 0.36 |
| ▸ | HTR2C | P28335 | 7/20 | 0.36 |
| ▸ | HRH1 | P35367 | 5/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.36 |
| ▸ | DRD1 | P21728 | 4/20 | 0.36 |
| ▸ | HTR7 | P34969 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5953153 | 0.87 | DRD2 (0.52) | DRD2DRD4TDP1CYP1A2CYP3A4 | |
| SCHEMBL5953611 | 0.85 | DRD2 (0.42) | DRD2DRD4TDP1CYP1A2CYP3A4 | |
| SCHEMBL9949394 | 0.75 | MAPT (0.48) | DRD2DRD4TDP1CYP1A2CYP3A4 | |
| SCHEMBL11715986 | 0.72 | DRD2 (0.48) | DRD2DRD4TDP1CYP1A2CYP3A4 | |
| SCHEMBL5953640 | 0.72 | PYCR1 (0.45) | DRD2DRD4TDP1CYP1A2CYP3A4 | |
| SCHEMBL1842504 | 0.72 | DRD2 (0.56) | DRD2DRD4TDP1CYP1A2CYP3A4 | |
| SCHEMBL7770728 | 0.71 | DRD2 (0.43) | DRD2DRD4TDP1CYP1A2CYP3A4 | |
| SCHEMBL5953604 | 0.70 | DRD2 (0.44) | DRD2DRD4TDP1CYP1A2CYP3A4 | |
| SCHEMBL5953534 | 0.69 | HTR2A (0.44) | DRD2DRD4TDP1CYP1A2CYP3A4 | |
| SCHEMBL5953114 | 0.69 | RORC (0.39) | DRD2DRD4DRD3TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060100269-A1 | Use of 10-aminoaliphatyl-dibenz[b,f]oxepines for the treatment of degenerative ocular disorders | LAMBROU GEORGE N | 2006-05-11 | — | — | US | claimed |
| EP-1589963-A1 | USE OF 10-AMINOALIPHATYL-DIBENZ B,F OXEPINES FOR THE TR EATMENT OF DEGENERATIVE OCULAR DISORDERS | Novartis AG (CH) | 2005-11-02 | — | — | EP | claimed |
| WO-2004066993-A1 | USE OF 10-AMINOALIPHATYL-DIBENZ[B,F]OXEPINES FOR THE TREATMENT OF DEGENERATIVE OCULAR DISORDERS | NOVARTIS AG (CH) | 2004-08-12 | — | — | WO | claimed |
| EP-0726265-A1 | 10-Aminoaliphatyl-dibenz(b,f)oxepins with antineurodegenarative activity | CIBA-GEIGY AG (CH) | 1996-08-14 | — | — | EP | claimed |
| US-20060100269-A1 | Use of 10-aminoaliphatyl-dibenz[b,f]oxepines for the treatment of degenerative ocular disorders | LAMBROU GEORGE N | 2006-05-11 | — | — | US | disclosed |
| EP-1589963-A1 | USE OF 10-AMINOALIPHATYL-DIBENZ B,F OXEPINES FOR THE TR EATMENT OF DEGENERATIVE OCULAR DISORDERS | Novartis AG (CH) | 2005-11-02 | — | — | EP | disclosed |
| WO-2004066993-A1 | USE OF 10-AMINOALIPHATYL-DIBENZ[B,F]OXEPINES FOR THE TREATMENT OF DEGENERATIVE OCULAR DISORDERS | NOVARTIS AG (CH) | 2004-08-12 | — | — | WO | disclosed |
| EP-0726265-A1 | 10-Aminoaliphatyl-dibenz(b,f)oxepins with antineurodegenarative activity | CIBA-GEIGY AG (CH) | 1996-08-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100269-A1 | Use of 10-aminoaliphatyl-dibenz[b,f]oxepines for the treatment of degenerative ocular disorders | DBH, MAOB, AADAT | DRD2 28/4885DRD4 79/4885TDP1 1867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.